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Sir,
We read with great interest the paper by Wilkowski et al (2009)
entitled ‘Chemoradiotherapy with concurrent gemcitabine
and cisplatin with or without sequential chemotherapy with
gemcitabine/cisplatin vs chemoradiotherapy with concurrent
5-fluorouracil in patients with locally advanced pancreatic cancer
– a multi-centre randomised phase II study’.
The authors reported the results of a multi-centre three-arm
randomised phase II trial involving patients with non-resectable
locally advanced pancreatic cancer (LAPC).
The purpose of the study was to compare three different
chemoradiotherapy (CRT) regimens in terms of efficacy and
tolerance. A 5-fluorouracil-based CRT protocol was selected as the
reference arm, whereas patients in the two other treatment arms
received CRT with concurrent low-dose gemcitabine and cisplatin.
In one treatment arm, patients also received sequential full-dose
chemotherapy with gemcitabine/cisplatin.
The objective of the study was to determine the anti-neoplastic
efficacy of the combined modality regimens, primarily the overall
survival rates at 9 months after randomisation. Secondary
objectives included the achievement of resectability after CRT,
progression-free survival, response rate, and toxicity.
The authors reported an overall 19% surgical resection after
primary CRT. It is noteworthy that they reported 25% resections in
patients assigned to primary radiotherapy with concurrent
gemcitabine and cisplatin without sequential chemotherapy.
These features would be very encouraging, meaning that up to a
quarter of the patients affected by non-resectable LAPC might benefit
from a primary CRT regimen in order to obtain a downstaging of the
disease and become suitable for radical surgery.
Usually pancreatic cancer is considered as resectable if a
potential curative surgical treatment is possible (Callery et al,
2009). Most of the patients diagnosed with pancreatic cancer are
unresectable at presentation because of the presence of distal
metastasis or because of locally advanced disease, that is,
peripancreatic extension of the disease in the absence of distant
metastasis (Cardenes et al, 2006).
This condition should be assessed by an experienced pancreatic
team, which should include at least a radiologist and a surgeon,
although it would be wiser to involve an endoscopist, a pathologist
and an oncologist in order to properly assess the resectability and
treatment strategies for each patient.
The encouraging results reported by Wilkowski et al regarding
the rate of surgical resections after primary CRT should be
interpreted in the light of the definition of LAPC adopted by the
authors. In fact they used the following definition: ‘yat least
one of the following CT findings: nodal involvement; retro-
peritoneal infiltration; infiltration of the superior mesenteric
artery, hepatic artery, superior mesenteric vein, or portal vein’.
We believe that this definition might not be appropriate, owing to
two reasons. First, it might be difficult, if not impossible, to clearly
determine peripancreatic nodal involvement and retroperitoneal
infiltration by a CT scan. Second, we feel that any experienced
pancreatic surgeon would not consider a patient as affected by
unresectable pancreatic cancer on the basis of a CT scan showing a
suspected nodal involvement or retroperitoneal infiltration, or, at
least for some degrees of involvement, infiltration of the superior
mesenteric vein or portal vein.
Therefore, we believe that the patients who underwent a surgical
resection in the study of Wilkowski et al, or at least some of them,
should be considered as patients with an overstaged disease at the
time of randomisation, rather than as patients who became
resectable after a downstaging treatment.
As other researchers have already done (Abrams et al, 2009), we
wish to focus on the importance of finding a unique, accepted
definition of resectable, border-line resectable and LAPC in order
to facilitate a comparison of future interventional clinical trials all
over the world.
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